%0 Journal Article
%T An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions.
%A Upshaw WC
%A Richey JM
%A Ravi G
%A Chen A
%A Ahmadzadeh S
%A Shekoohi S
%A Viswanath O
%A Kaye AD
%J Expert Opin Investig Drugs
%V 33
%N 8
%D 2024 Aug 8
%M 38973395
%F 6.498
%R 10.1080/13543784.2024.2376570
%X <B>UNASSIGNED: </B>LX-9211 is a drug designed to treat neuropathic pain conditions. It functions by inhibiting the adaptor-associated kinase 1 (AAK1) enzyme which promotes clathrin-dependent endocytosis. Preclinical studies have shown that LX-9211 does produce a reduction in nociceptive related behaviors and produces no major adverse effects in rats. Thus, LX-9211 has advanced to clinical trials to assess its safety and efficacy in humans. So far, phase 1 and phase 2 clinical trials involving patients with postherpetic neuralgia and diabetic peripheral neuropathic pain have been conducted with phase 3 trials planned in the future.<BR><B>UNASSIGNED: </B>This paper highlights preclinical studies involving LX-9211 in rodents. Additionally, phase 1 clinical trials examining the safety of LX-9211 in healthy subjects as well as phase 2 studies looking at the safety and efficacy of LX-9211 compared to placebo in patients with diabetic peripheral neuropathic pain and postherpetic neuralgia are also discussed.<BR><B>UNASSIGNED: </B>In phase 1 and phase 2 clinical trials conducted so far, LX-9211 has been shown to produce few adverse effects as well as cause a significantly greater reduction in pain compared to placebo. However, more clinical studies are needed to further assess its effects in humans to ensure its safety.